Business Description
Catalyst Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US14888U1016
Total Employee Number:
182Description
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 281.93 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-EBITDA | 0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 19.98 | |||||
Beneish M-Score | -1.84 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 34 | |||||
3-Year EBITDA Growth Rate | 35.9 | |||||
3-Year EPS without NRI Growth Rate | 38.7 | |||||
3-Year FCF Growth Rate | 16.3 | |||||
3-Year Book Growth Rate | 39.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 10.65 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 60.83 | |||||
9-Day RSI | 66.71 | |||||
14-Day RSI | 70.17 | |||||
3-1 Month Momentum % | 25.18 | |||||
6-1 Month Momentum % | 38.49 | |||||
12-1 Month Momentum % | 45.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.1 | |||||
Quick Ratio | 6.84 | |||||
Cash Ratio | 5.71 | |||||
Days Inventory | 120.67 | |||||
Days Sales Outstanding | 61.25 | |||||
Days Payable | 38.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.2 | |||||
Shareholder Yield % | 0.39 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 85.96 | |||||
Operating Margin % | 44.83 | |||||
Net Margin % | 37.08 | |||||
EBITDA Margin % | 51.23 | |||||
FCF Margin % | 34.87 | |||||
OCF Margin % | 34.88 | |||||
ROE % | 24.39 | |||||
ROA % | 21.35 | |||||
ROIC % | 81.33 | |||||
3-Year ROIIC % | 57.11 | |||||
ROC (Joel Greenblatt) % | 970.63 | |||||
ROCE % | 29.4 | |||||
Years of Profitability over Past 10-Year | 7 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 18.1 | |||||
Forward PE Ratio | 16.13 | |||||
PE Ratio without NRI | 15.66 | |||||
Shiller PE Ratio | 53.38 | |||||
Price-to-Owner-Earnings | 25.64 | |||||
PEG Ratio | 0.35 | |||||
PS Ratio | 6.71 | |||||
PB Ratio | 3.8 | |||||
Price-to-Tangible-Book | 4.32 | |||||
Price-to-Free-Cash-Flow | 19.26 | |||||
Price-to-Operating-Cash-Flow | 19.25 | |||||
EV-to-EBIT | 11.58 | |||||
EV-to-Forward-EBIT | 11.06 | |||||
EV-to-EBITDA | 10.14 | |||||
EV-to-Revenue | 5.19 | |||||
EV-to-Forward-Revenue | 4.9 | |||||
EV-to-FCF | 14.89 | |||||
Price-to-GF-Value | 1.28 | |||||
Price-to-Projected-FCF | 1.49 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.63 | |||||
Price-to-Graham-Number | 1.73 | |||||
| Price-to-Net-Current-Asset-Value | 4.78 | |||||
| Price-to-Net-Cash | 6.2 | |||||
Earnings Yield (Greenblatt) % | 8.64 | |||||
FCF Yield % | 5.4 | |||||
Forward Rate of Return (Yacktman) % | 23.71 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CPRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Catalyst Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 596.958 | ||
| EPS (TTM) ($) | 1.74 | ||
| Beta | 0.7751 | ||
| 3-Year Sharpe Ratio | 0.98 | ||
| 3-Year Sortino Ratio | 1.69 | ||
| Volatility % | 22.6 | ||
| 14-Day RSI | 70.17 | ||
| 14-Day ATR ($) | 0.113067 | ||
| 20-Day SMA ($) | 31.3825 | ||
| 12-1 Month Momentum % | 45.71 | ||
| 52-Week Range ($) | 19.05 - 32.56 | ||
| Shares Outstanding (Mil) | 122.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Catalyst Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Catalyst Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:30 | In 123 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 121 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 08:30 | In 32 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 30 days | ||
| General meeting for 2025 | 2026-07-08 09:00 | In 2 days | ||
| First quarter earnings results for 2026 | 2026-05-11 | 31.15 (+0.03%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-10 15:30 | 24.79 (+2.86%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-26 08:30 | 24.86 (+2.47%) | ||
| Annual report for 2025 | 2026-02-25 | 24.19 (+0.62%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-25 | 24.19 (+0.62%) |
Show
Entries
Catalyst Pharmaceuticals Inc Frequently Asked Questions
What is Catalyst Pharmaceuticals Inc(CPRX)'s stock price today?
The current price of CPRX is $31.50. The 52 week high of CPRX is $32.56 and 52 week low is $19.05.
When is next earnings date of Catalyst Pharmaceuticals Inc(CPRX)?
The next earnings date of Catalyst Pharmaceuticals Inc(CPRX) is 2026-08-06 Est..
Does Catalyst Pharmaceuticals Inc(CPRX) pay dividends? If so, how much?
Catalyst Pharmaceuticals Inc(CPRX) does not pay dividend.
Guru Commentaries on NAS:CPRX
No articles.
Press Release
Articles on Catalyst Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers